Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Pirtobrutinib Offers Potential Second-Line Treatment in CLL

September 26th 2025

Jennifer A. Woyach, MD, discusses the potential of pirtobrutinib as a second-line option for patients with CLL.

First-Line Atebimetinib Plus mGnP Yields High 9-Month OS Rate in Pancreatic Cancer

September 25th 2025

Atebimetinib plus modified gemcitabine/nab-paclitaxel continued to elicit high OS rates in patients with treatment-naive pancreatic cancer.

FDA Grants Fast Track Designation to Alnodesertib Plus Irinotecan in ATM-Negative mCRC

September 24th 2025

Alnodesertib has received fast track designation from the FDA for patients with ATM-negative metastatic colorectal cancer.

FDA Grants Priority Review to First-Line T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer

September 24th 2025

Frontline T-DXd plus pertuzumab is under FDA priority review for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.

Personalized Approaches Are Emerging for GVHD in Hematologic Malignancies

September 24th 2025

A panel of hematologic cancer experts discusses data on GVHD management from the 2025 SOHO Annual Meeting.

Linvoseltamab Adds Highly Effective Option in Later-Line Multiple Myeloma

September 23rd 2025

Hans Lee, MD; and Nisha Joseph, MD, discuss the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

New T-DXd Data Have the Potential to Reorder ADC Sequencing in HER2+ Breast Cancer

September 22nd 2025

Naoto T. Ueno, MD, PhD, FACP, discusses treatment sequencing considerations in HER2+ advanced or metastatic breast cancer.

Subcutaneous Isatuximab Delivery Is Noninferior to IV Administration in Multiple Myeloma

September 20th 2025

Efficacy and pharmacokinetic measures with IV vs SC isatuximab delivered via an on-body injector were comparable in patients with multiple myeloma.

Stretched Dosing Schedule of Belantamab Mafodotin Plus VRd Is Active, Safe in Transplant-Ineligible Myeloma

September 19th 2025

The addition of belantamab mafodotin to standard-of-care VRd proved feasible as frontline therapy in newly diagnosed multiple myeloma.

D-VRd Produces Favorable PROs and Safety Outcomes in MRD-Negative Newly Diagnosed Multiple Myeloma

September 19th 2025

D-VRd led to favorable PRO outcomes in patients with newly diagnosed multiple myeloma who had MRD negativity after therapy.

Orca-T Delivers Major Gains Beyond Conventional Prophylaxis in Hematologic Malignancies

September 19th 2025

David Miklos, MD, PhD, discusses the potential role for Orca-T vs standard PTCy after allogeneic transplant in hematologic malignancies.

Retifanlimab Displaces Chemo Alone as the Frontline Standard of Care in SCAC

September 17th 2025

Retifanlimab is the first and only immunotherapy agent to receive an indication for the frontline treatment of patients with advanced SCAC.

Optune Lua Secures Japanese Approval for Advanced NSCLC

September 17th 2025

Optune Lua plus concurrent PD-1/PD-L1 inhibition has been approved in Japan for advanced non–small cell lung cancer after platinum-based chemotherapy.

FDA Approves 2 Denosumab Biosimilars in High Fracture Risk Populations, Including in Breast and Prostate Cancer

September 17th 2025

Two denosumab biosimilars received approval from the FDA for the purpose of increasing bone mass in individuals at high risk for fracture.

Osimertinib Plus Chemotherapy Expands Frontline Choices in EGFR+ NSCLC

September 16th 2025

In an OncLive Peer Exchange, a panel of lung cancer experts discussed updated data in EGFR-mutated NSCLC from WCLC 2025.

FDA Approval of Belzutifan Provides Needed Option in Pheochromocytoma or Paraganglioma

September 16th 2025

The FDA approval of belzutifan in patients with pheochromocytoma or paraganglioma is a testament to the power of drug discovery in rare tumor subsets.

Neoadjuvant Tislelizumab Plus Chemo Drives Responses in Locally Advanced Cervical Cancer

September 15th 2025

Neoadjuvant tislelizumab plus chemotherapy yielded responses in locally advanced cervical cancer.

BTK Inhibitors Lead to Decreased Health Care Resource Utilization in MCL

September 15th 2025

BTK inhibitors were associated with lower health care resource utilization vs other regimens in mantle cell lymphoma.

OncLive Fellows Forum Spotlights New Data for Tarlatamab in SCLC and PRO Results in Hospitalized Patients

September 13th 2025

Kelsey Pan, MD, MPH, discusses notable presentations from an OncLive Fellows Forum on Thoracic Oncology.

Amivantamab Plus Lazertinib Yields OS Advantage in Asia Cohort of MARIPOSA Trial in EGFR-Mutated NSCLC

September 12th 2025

Frontline amivantamab plus lazertinib generated an OS benefit vs osimertinib in patients with EGFR-mutated NSCLC in the Asia cohort of the MARIPOSA trial.